A late-stage clinical trial evaluating a three-drug combination for renal cell carcinoma (RCC) did not achieve its primary objectives, according to results released by Merck and Eisai. The regimen under investigation brought together Merck’s PD-1 inhibitor Keytruda, its HIF-2α inhibitor Welireg, and Eisai’s tyrosine kinase inhibitor Lenvima. Each of these therapies has previously received regulatory approval for use in various cancer indications.
The Phase 3 LITESPARK-012 study examined the triplet regimen as a first-line treatment option for patients diagnosed with RCC. Despite this approach, the companies reported that the therapy did not meet its dual primary endpoints, which were overall survival and progression-free survival. Within the study design, patients assigned to the control arm were treated with a two-drug combination consisting of Keytruda alongside Lenvima.
Specific efficacy data from the trial were not disclosed in the announcement. Instead, the companies indicated that the three-drug regimen did not produce a statistically significant improvement in survival outcomes when compared with the established doublet therapy. The trial enrolled a total of 1,688 participants and also included an evaluation of an additional investigational combination. This second regimen paired Lenvima with MK-1308A, which is a co-formulation combining Keytruda with the experimental antibody quavonlimab. Findings from an interim analysis showed that neither of the combinations tested in the study demonstrated superior results relative to the Keytruda-Lenvima regimen.
Overall survival remains a central measure in oncology clinical trials, as it reflects the duration of time patients live following either diagnosis or the initiation of treatment. The absence of improvement in this endpoint suggests that adding Welireg to the existing combination did not increase treatment effectiveness in this particular setting.
Corina Ductus, Oncology Global Clinical Development Lead at Eisai, addressed the findings in a prepared statement, stating that the companies were “disappointed” with the outcome while noting that such results still contribute to the broader understanding of treatment strategies for RCC as they continue to develop.
The companies also reported that the safety profile observed for the combinations under investigation was consistent with findings from previous studies. In addition, both Merck and Eisai stated that they are continuing to conduct a full and detailed evaluation of the data generated from the trial.
The results may influence how Welireg is positioned in the treatment landscape for RCC going forward. Analyst Carter Gould indicated that the findings could delay a potential pathway toward first-line approval for the drug and may also impact expectations regarding its commercial performance. He projected that Welireg could reach $1 billion in sales by 2026, with peak sales estimated at $2 billion by 2035. In the most recent reported year, the drug generated $716 million in revenue.
Despite the outcome of LITESPARK-012, the companies confirmed that these findings do not affect other ongoing trials within the broader LITESPARK clinical program. Among these is the Phase 3 LITESPARK-033 study, which is evaluating Welireg in combination with zanzalintinib and is expected to reach completion in 2032.
Merck and Eisai have collaborated on oncology research since 2015, when they first entered into a clinical trial agreement to explore combinations involving Keytruda, Lenvima, and Eisai’s breast cancer therapy Halaven. This collaboration was expanded further in 2018 through a multibillion-dollar agreement aimed at jointly developing and commercializing combination treatment regimens.
The Keytruda-Lenvima combination therapy continues to hold approvals across multiple regions, including the United States, the European Union, Japan, and other countries, where it is used as a first-line treatment option for adult patients with advanced RCC.
Overview of RCC Trial Outcome
Merck & Co. and Eisai have reported disappointing results from a Phase 3 study evaluating a three-drug combination therapy for RCC (renal cell carcinoma). The trial failed to meet its primary survival endpoints, marking a setback in advancing new treatment options for RCC patients.
Details of RCC Combination Therapy
The combination regimen, which included immunotherapy and targeted therapy components, was designed to improve overall survival outcomes in advanced RCC. Despite strong scientific rationale, the therapy did not demonstrate a statistically significant benefit compared to existing standard treatments for RCC.
Why the RCC Trial Fell Short
Clinical trials in RCC are highly complex due to disease heterogeneity and varying patient responses. Factors such as trial design, patient selection, and competing therapies may have influenced the outcome. The results highlight the ongoing challenges in improving survival rates in advanced RCC.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
